-
2024-516372-14-00
11
2025-01-13
Asymptomatic Patients with frequent PVCs and normal LVEF
-
2023-506942-22-01
4
2025-01-10
paraneoplastic sensory neuropathy with anti-Hu antibodies
-
2023-509811-98-00
4
2025-01-07
Patients with HER2-positive locally advanced inoperable or metastatic
-
2023-507254-32-00
5
2024-12-17
Severe hyponatremia and a high risk of rapid SNa overcorrection
-
2024-514313-35-00
6
2024-12-03
Arthritis rheumatoid
-
2023-508400-38-00
4
2024-11-29
meningioma
-
2023-508208-40-00
10
2024-11-21
All adult patients with successful transfemoral trans-aortic valve imp
-
2023-508704-37-00
5
2024-11-08
Stroke
-
2024-514567-26-00
7
2024-11-08
glioblastoma
-
2023-509912-27-00
5
2024-11-07
Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
-
2024-514886-21-00
6
2024-11-06
Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus
(P
-
2024-516242-19-00
5
2024-11-05
lupus nephritis
-
2024-514606-31-00
4
2024-10-29
Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eli
-
2024-516101-23-00
5
2024-10-28
Sarcoidosis
-
2023-504755-26-00
4
2024-10-21
Bronchiectasis
-
2023-508614-41-00
4
2024-10-15
The study will be proposed to all adult patients receiving an allogene
-
2024-514610-13-00
5
2024-10-04
patients suffering from acute myocarditis confirmed on Cardiac magneti
-
2024-517845-14-00
4
2024-10-03
Relapsing Remitting Multiple sclerosis
-
2023-506642-23-01
4
2024-08-28
Active Pulmonary Sarcoidosis
-
2024-514481-39-00
4
2024-08-23
Ischemic stroke
-
2023-507692-21-00
3
2024-08-22
Bullous pemphigoid
-
2023-505363-37-00
1
2024-08-12
Myotonic dystrophy type 1 (DM1)
-
2023-506503-26-00
5
2024-07-31
Polyneuropathy, Inflammatory Demyelinating, Chronic
-
2022-502155-65-00
5
2024-07-30
Extra pulmonary sarcoidosis